Clinical Trial Update: A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) [Phase 3]

View source ↗

Summary

This document reports an ongoing Phase 3 trial evaluating rilvegostomig or durvalumab plus chemotherapy as first-line treatment for biliary tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Rilvegostomig (rilvegostomig)

Snippet

Sponsor: AstraZeneca | Conditions: Biliary Tract Cancer | Phase 3 | Status: RECRUITING